Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. (EVLO) Healthcare & Pipeline Overview

Evelo Biosciences, Inc. is a biotechnology firm developing oral biologic therapies for inflammatory conditions and oncology. Its pipeline features EDP1815 in Phase 2 for psoriasis and atopic dermatitis, alongside other candidates like EDP1867, EDP2939, and EDP1908, aiming to address significant unmet medical needs through its innovative whole-microbe and extracellular vesicle platforms.

What Is the Investment Thesis for EVLO?

Evelo Biosciences, Inc. presents an investment thesis centered on its innovative oral biologic pipeline targeting inflammatory diseases and oncology. The company's lead candidate, EDP1815, is in Phase 2 clinical trials for psoriasis and atopic dermatitis, with additional evaluation for COVID-19 hyperinflammation, representing significant market opportunities if successful. Further pipeline assets, including EDP1867 (Phase 1b for inflammatory diseases), EDP2939 (extracellular vesicle biologic for inflammatory diseases), and EDP1908 (oncology), demonstrate a diversified approach to addressing unmet medical needs. The company's focus on oral biologics could offer a differentiated therapeutic modality with potential advantages in patient convenience and adherence compared to injectable treatments. With a reported Beta of 1.32, the stock exhibits higher volatility relative to the broader market. As an early-stage biotechnology firm with a market capitalization of 2K, its valuation is primarily driven by clinical trial progress, intellectual property development, and the potential for future commercialization or partnership agreements. Key catalysts include positive data readouts from ongoing clinical trials, particularly for EDP1815, and advancement of its earlier-stage programs. Risks are inherent in drug development, including trial failures, regulatory hurdles, and financing requirements for a company without current revenue streams.

Based on FMP financials and quantitative analysis

EVLO Key Highlights

• Market Capitalization: $0.00 billion, reflecting its early-stage development and position as a micro-cap biotechnology company.
• Beta: 1.32, indicating higher volatility compared to the overall market, typical for biotechnology firms with pipeline-driven valuations.
• Dividend Yield: None, as the company is focused on reinvesting capital into research and development, consistent with its growth-oriented biotechnology business model.
• Lead Candidate Progress: EDP1815 is actively undergoing Phase 2 clinical trials for psoriasis and atopic dermatitis, representing a critical stage in its development pathway.
• Diversified Pipeline: The company maintains a pipeline of four distinct oral biologic candidates, including EDP1815, EDP1867, EDP2939, and EDP1908, targeting both inflammatory diseases and oncology.

Who Are EVLO's Competitors?

EVLO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EVLO's Key Strengths?

• Innovative oral biologic pipeline targeting significant unmet medical needs in inflammatory diseases and oncology.
• Lead candidate, EDP1815, is in Phase 2 clinical trials, indicating tangible progress in drug development.
• Diversified pipeline with multiple candidates (EDP1867, EDP2939, EDP1908) exploring different mechanisms within the oral biologic space.
• Focus on oral administration could offer patient convenience and adherence advantages over injectable therapies.

What Are EVLO's Weaknesses?

• Early-stage company with no current revenue streams, relying heavily on financing for research and development.
• High financial risk associated with clinical trial failures and regulatory hurdles inherent in biotechnology.
• Market capitalization of 2K suggests limited financial resources and market presence.
• Operating in a highly competitive industry against well-established pharmaceutical giants with extensive resources.

What Could Drive EVLO Stock Higher?

• Phase 2 Clinical Trial Readouts for EDP1815: Positive data readouts from the ongoing Phase 2 trials for EDP1815 in psoriasis and atopic dermatitis would be a significant catalyst, validating the drug's potential and Evelo's platform.
• Advancement of EDP1867 into Later-Stage Trials: Successful completion of Phase 1b for EDP1867 and its progression into Phase 2 for inflammatory diseases would demonstrate pipeline momentum and de-risk the asset.
• Further Development of EDP2939 and EDP1908: Continued progress in preclinical or early clinical development for EDP2939 (inflammatory diseases) and EDP1908 (oncology) would signal a robust and expanding pipeline.
• Data on EDP1815 for COVID-19 Hyperinflammation: Any updates or data from the evaluation of EDP1815 for the hyperinflammatory reaction associated with COVID-19 could provide additional validation and open new therapeutic avenues.

What Are the Key Risks for EVLO?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical Trial Failure: The primary risk is the failure of any of Evelo's drug candidates, particularly EDP1815, to meet primary endpoints in clinical trials or demonstrate an acceptable safety profile, leading to significant value impairment.
• Regulatory Hurdles: The drug development process is subject to stringent and unpredictable regulatory approvals, which can delay or prevent market entry even for successful clinical candidates.
• Funding and Liquidity Challenges: As an early-stage biotech with no current revenue and a market cap of 2K, Evelo faces ongoing challenges in securing sufficient funding for its extensive R&D, potentially leading to dilution or operational constraints.
• Intense Competition: The inflammatory disease and oncology markets are highly competitive, with numerous established and emerging therapies, posing a threat to market adoption even if Evelo's drugs are approved.
• OTC Market Risks: Trading on the OTC Other tier with unknown disclosure status exposes investors to risks of low liquidity, high volatility, and limited access to critical company information.

What Are the Growth Opportunities for EVLO?

• The successful progression of EDP1815 through its ongoing Phase 2 clinical trials for psoriasis and atopic dermatitis represents a significant growth opportunity. These conditions affect millions globally, with existing treatments often having side effects or requiring inconvenient administration. If EDP1815 demonstrates positive efficacy and safety data, it could unlock a substantial market, potentially offering an oral, whole-microbe alternative that improves patient adherence and quality of life. Positive trial results could attract partnership opportunities or facilitate further funding, accelerating its path to market.
• Evelo's development of EDP1908 for oncology opens a vast and critical therapeutic area. Cancer remains a leading cause of mortality worldwide, driving continuous demand for innovative treatments. While in earlier stages, successful development of an oral biologic for cancer could provide a novel mechanism of action, potentially complementing or improving upon existing therapies. The oncology market is characterized by high unmet needs and significant commercial potential for breakthrough treatments, offering a long-term growth vector for Evelo Biosciences.
• The company's underlying technology platform, focused on oral biologics derived from whole-microbes and extracellular vesicles, represents a foundational growth opportunity. Beyond its current pipeline, this platform has the potential to generate additional drug candidates for a wider array of inflammatory, autoimmune, and potentially other diseases. The ability to discover and develop multiple assets from a proprietary platform can create a sustainable pipeline, reducing reliance on single drug candidates and expanding the company's addressable market over time.
• The ongoing development of EDP1867 (Phase 1b) and EDP2939 (investigational) for inflammatory diseases provides further diversification within a key therapeutic area. These candidates offer different mechanisms (inactivated oral biologic, extracellular vesicles) compared to EDP1815, potentially addressing different patient populations or disease subtypes. Successful advancement of these programs could strengthen Evelo's position in the inflammatory disease market, providing multiple shots on goal and increasing the likelihood of bringing a successful product to market.
• The evaluation of EDP1815 for the hyperinflammatory reaction associated with COVID-19 presents a timely and potentially impactful growth opportunity. While the pandemic's immediate crisis may subside, the understanding and treatment of severe inflammatory responses remain critical in various viral infections and acute conditions. If EDP1815 proves effective in this context, it could open up new therapeutic avenues beyond chronic inflammatory diseases, demonstrating the versatility and broad utility of Evelo's lead candidate.

What Opportunities Does EVLO Have?

• Successful clinical trial outcomes for EDP1815 could validate the oral biologic platform and attract significant partnerships or investment.
• Expansion into new therapeutic areas or indications using its proprietary platform technology.
• Potential for EDP1815 to address the hyperinflammatory response associated with COVID-19, opening new market segments.
• Strategic collaborations with larger pharmaceutical companies to accelerate development and commercialization of pipeline assets.

What Threats Does EVLO Face?

• Failure of clinical trials to demonstrate efficacy or safety, leading to abandonment of drug candidates.
• Intense competition from existing therapies and other novel treatments in development for inflammatory diseases and oncology.
• Stringent and unpredictable regulatory approval processes, which can delay or prevent market entry.
• Need for substantial capital raises, potentially leading to dilution for existing shareholders if not successful.

What Are EVLO's Competitive Advantages?

• Proprietary Oral Biologic Platform: Development of unique whole-microbe and extracellular vesicle-based oral biologics represents a differentiated scientific approach.
• Clinical Pipeline: Advanced-stage candidates like EDP1815 in Phase 2 trials provide a head start in specific therapeutic areas.
• Intellectual Property: Patents and trade secrets protecting its drug candidates and underlying technology platform.
• Scientific Expertise: Specialized knowledge and experience in microbiome science and immunology required to develop these novel therapies.

What Does EVLO Do?

Evelo Biosciences, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, operates as a biotechnology firm singularly focused on the discovery and advancement of oral biologic therapies. The company's strategic mission revolves around leveraging the potential of the human microbiome to develop novel treatments for a spectrum of inflammatory conditions and oncological diseases. At the core of its innovative pipeline is EDP1815, a pioneering whole-microbe compound. This candidate is currently undergoing rigorous Phase 2 clinical trials, specifically targeting chronic inflammatory ailments such as psoriasis and atopic dermatitis, which represent significant global health burdens. Beyond these conditions, EDP1815 is also being evaluated for its potential in mitigating the hyperinflammatory reaction associated with COVID-19, highlighting its broad therapeutic applicability. Evelo's commitment to expanding its oral biologic platform is further demonstrated through additional pipeline developments. These include EDP1867, an inactivated oral biologic that is progressing through Phase 1b trials for various inflammatory diseases, indicating the company's continuous efforts to diversify its therapeutic approaches. Furthermore, the company is advancing EDP2939, an investigational oral biologic derived from extracellular vesicles, also aimed at inflammatory diseases, which underscores Evelo's exploration of cutting-edge biological mechanisms. In a strategic move to address a different critical area of medical need, Evelo Biosciences is also developing EDP1908, a drug candidate specifically focused on oncology. This diversified pipeline reflects Evelo's comprehensive approach to drug development, aiming to provide convenient, oral alternatives to existing treatments, potentially improving patient adherence and outcomes across multiple complex disease areas. The company's operations are supported by a team of 66 employees, driving its research and development efforts from its Cambridge, US base.

What Products and Services Does EVLO Offer?

• Discovers and develops oral biologic therapies for various diseases.
• Focuses on inflammatory conditions such as psoriasis and atopic dermatitis.
• Also develops drug candidates for oncological diseases.
• Utilizes a whole-microbe compound, EDP1815, for inflammatory ailments.
• Investigates inactivated oral biologics like EDP1867 for inflammatory diseases.
• Explores extracellular vesicle-based oral biologics, such as EDP2939.
• Develops EDP1908 as a product candidate specifically for cancer treatment.
• Conducts clinical trials, with EDP1815 currently in Phase 2 for multiple indications.

How Does EVLO Make Money?

• Research and Development: Primarily invests in the discovery and preclinical/clinical development of novel oral biologic drug candidates.
• Pipeline Monetization: Aims to generate revenue through successful clinical trial outcomes, leading to regulatory approval and subsequent commercialization of its drug products.
• Partnerships and Licensing: May pursue strategic collaborations, licensing agreements, or co-development deals with larger pharmaceutical companies to fund development, share risks, and leverage commercialization infrastructure.
• Intellectual Property: Builds and maintains a portfolio of patents and proprietary knowledge around its oral biologic platform and drug candidates to protect future revenue streams.

What Industry Does EVLO Operate In?

Evelo Biosciences, Inc. operates within the highly specialized and competitive biotechnology industry, a sub-sector of healthcare. This industry is characterized by extensive research and development, long drug development cycles, and significant regulatory oversight. Evelo's niche is the development of oral biologic therapies, a novel approach that seeks to harness the body's own biological mechanisms, particularly those related to the microbiome, to treat complex diseases. The broader biotechnology market is driven by advancements in genomics, immunology, and personalized medicine, with a growing emphasis on innovative drug delivery methods and treatments for chronic and rare diseases. Evelo's focus on inflammatory conditions like psoriasis and atopic dermatitis places it in a therapeutic area with substantial patient populations and ongoing demand for more effective and convenient treatments. The oncology pipeline further positions the company in one of the largest and most research-intensive segments of the pharmaceutical market. Competition is intense, encompassing large pharmaceutical companies, established biotechs, and numerous emerging firms, all vying for market share through novel drug discoveries and clinical successes. Evelo's differentiation lies in its oral biologic platform, which could offer a unique competitive advantage if clinical trials demonstrate efficacy and safety.

Who Are EVLO's Key Customers?

• Patients: Individuals suffering from inflammatory conditions like psoriasis, atopic dermatitis, or cancer, who would ultimately receive the approved therapies.
• Healthcare Providers: Physicians, specialists (dermatologists, oncologists, immunologists), and hospitals who prescribe and administer treatments.
• Pharmaceutical Partners: Larger pharmaceutical companies that may license or acquire Evelo's drug candidates for further development, manufacturing, and global commercialization.
• Payers: Insurance companies and government health programs that cover the cost of approved treatments.

Net sellingInsider Activity

The most recent 12 insider filings for Evelo Biosciences, Inc. break down as 8 sales and 4 purchases. On net that is roughly 8K shares disposed (about $3K), a signal worth weighing alongside the fundamentals.

FY2026 estForward Outlook

Wall Street analysts project Evelo Biosciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.40.

F-Score 3/9Financial Health

Evelo Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Evelo Biosciences, Inc. (EVLO) Valuation Context

Valued at 2K, EVLO is classified as a micro-cap stock. Relative to its peer group, EVLO's quantitative score of 48/100 is below the peer average of 76/100.

Company Profile

Evelo Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Craig R. Jalbert. EVLO has traded publicly since 2018.

EVLO Financials

EVLO Latest News

EVLO Analyst Consensus

EVLO MoonshotScore

EVLO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources